Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29868499 | 1.00 | KDM4E (0.56) | KDM4EHSD17B10EGFRCA1CA2 | |
| SCHEMBL6535966 | 0.86 | ADORA3 (0.50) | KDM4EHSD17B10EGFRCA1CA2 | |
| SCHEMBL6769062 | 0.85 | ERN1 (0.48) | MAPTERN1KMT2AMEN1 | |
| SCHEMBL2044179 | 0.85 | CA1 (0.51) | EGFRCA1CA2MAPTERN1 | |
| SCHEMBL29788180 | 0.85 | CA1 (0.51) | EGFRCA1CA2MAPTERN1 | |
| SCHEMBL1617752 | 0.82 | ERN1 (0.51) | KDM4EHSD17B10CA1CA2MAPT | |
| SCHEMBL31238859 | 0.80 | MAPT (0.58) | KDM4EEGFRCA1CA2MAPT | |
| SCHEMBL10459227 | 0.79 | KDM4E (0.46) | KDM4EHSD17B10EGFRCA1CA2 | |
| SCHEMBL2050621 | 0.77 | EGFR (0.56) | EGFRCA1CA2MAPT | |
| SCHEMBL21182648 | 0.77 | EGFR (0.56) | KDM4EEGFRCA1CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673814-B2 | CONTROLLED-RELEASE BY IMPLANTABLE DEVICES, DELIVERY PUMPS, WAFERS, AND BIODEGRADABLE POLYMERS | EMORY UNIVERSITY | 2004-01-06 | — | — | US | disclosed |
| US-20020137762-A1 | Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents | EMORY UNIVERSITY | 2002-09-26 | — | — | US | disclosed |
| US-6376516-B1 | FOR TREATING NEOPLASTIC CANCERS INCLUDING COLON, LUNG, BRAIN, OVARIAN, PROSTATE, BREAST, AND BLADDER CANCER AND LEUKEMIA; LOW TOXICITY | EMORY UNIVERSITY | 2002-04-23 | — | — | US | disclosed |
| WO-1999008528-A1 | NOSCAPINE DERIVATIVES, USEFUL AS ANTICANCER AGENTS | EMORY UNIVERSITY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137762-A1 | Delivery systems and methods for noscapine and noscapine derivatives, useful as anticancer agents | NOS1, NOS2, HCCS | KDM4E 2873/4885HSD17B10 1421/4885EGFR 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.